ISU104

ISU Abxis Co., Ltd. · Phase 1 active Biologic

At a glance

Generic name	ISU104
Also known as	A human monoclonal antibody targeting ErbB3
Sponsor	ISU Abxis Co., Ltd.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ISU104 CI brief — competitive landscape report
ISU104 updates RSS · CI watch RSS
ISU Abxis Co., Ltd. portfolio CI